• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Glucagon-like peptide-1 receptor agonist may reduce incidence of diabetic retinopathy

byDavy LauandAlex Chan
February 9, 2023
in Chronic Disease, Endocrinology, Ophthalmology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with Type 2 Diabetes taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have a lower incidence of diabetic retinopathy (DR), compared to those not taking GLP-1 RAs.

2. A Mendelian randomization analysis found that an increase in GLP1R gene expression was associated with decreased risk for background and severe nonproliferative DR subtypes, but not proliferative DR and overall DR.

Evidence Rating Level: 2 (Good)

Diabetic retinopathy (DR) affects greater than 100 million individuals internationally. It can be classified into 3 types (in order of severity): Background DR, severe nonproliferative DR, and proliferative DR. Currently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are diabetes medications associated with reductions in cardiovascular morbidity and mortality, as well as stroke. However, they have also been hypothesized to reduce the risk of DR, since the expression of GLP1R, the target of GLP-1 RAs, are prevalent in the retina. The current population matched cohort study based in Sweden examined the incidence of DR amongst patients with diabetes who did and did not use GLP-1 RAs, and also conducted a summary-data-based Mendelian randomization analysis. The cohort consisted of patients diagnosed with Type 2 Diabetes between 2006 and 2015, with each patient using GLP-1 RAs matched to randomly selected patients not using GLP-1 RAs, matched by age, sex, and duration of disease. The Mendelian analysis used single nucleotide polymorphisms (SNPs) associated with GLP1R expression in the pancreas, and correlated that with DR outcomes. In total, there were 14,119 patients included, with 2390 taking GLP-1 RAs and 11,729 patients who did not use GLP-1 RAs. The median (IQR) follow-up time was 2.03 (1.07-3.18) years for those using GLP-1 RAs and 1.92 (0.99-3.47) years for those not using GLP-1 RAs. The study found that the incidence of DR was 5.97 per 1000 person-years for GLP-1 RA users and 12.85 per 1000 person-years for non-users. Therefore, the incidence of DR was significantly lower in GLP-1 RA users (HR 0.43, 95% CI 0.29-0.61, p < 0.0001). Additionally, the Mendelian randomization analysis found that an increase in GLP1R expression by 1 standard deviation was associated with lower background DR risk (OR 0.83, 95% CI 0.71-0.97, p = 0.0162) and severe nonproliferative DR (OR 0.72, 95% CI 0.53-0.98, p = 0.0355), but not overall DR and proliferative DR. Overall, this study demonstrated through a population-based cohort analysis and a Mendelian randomization analysis that GLP-1 RAs are associated with decreased risk of developing DR.

Click to read the study in BMC Medicine

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

The Scan by 2 Minute Medicine®: Erythritol and Heart Problems, Maternal Health Trends, the Next Big Thing in Diabetes, and Declining Levels of Sea Ice

Tags: diabetesdiabetic retinopathyGLP-1 receptor agonists
Previous Post

Meningococcal group B vaccine effective at preventing meningococcal disease in children

Next Post

Spirituality has mixed effects on outcomes in ALS patients and caregivers

RelatedReports

Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

March 21, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Erythritol and Heart Problems, Maternal Health Trends, the Next Big Thing in Diabetes, and Declining Levels of Sea Ice

March 7, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Black History Month, Mr.Beast, Damar Hamlin and on-field CPR, Ozempic Shortage

March 14, 2023
Next Post
Early palliative care may improve survival in advanced cancer

Spirituality has mixed effects on outcomes in ALS patients and caregivers

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Anthracycline may be associated with increased incidence of heart failure

Prevalence of hypertension among adolescents varies by race and BMI

Telephone health coaching intervention ineffective for improving outcomes for hypertension

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Febuxostat may be effective in preventing contrast-induced acute kidney injury
  • Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
  • United States patients receive subcutaneous fluids less frequently than intravenous fluids when compared to Canadian patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options